Ultragenyx Pharmaceutical | RARE - Fremdkapital

Aktienkurs
23.30
Täglich Wechseln
-0.61 -2.55%
Monatlich
4.91%
Jährlich
-31.75%
Q2 Prognose
22.66




Fremdkapital Veränderung Datum
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Immunic USD 0 0 2024-06
Insmed USD 540.96M 1.24M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Kyowa Hakko Kirin JPY 24.12B 5.27B 2024-12
MacroGenics USD 70M 256K 2025-12
Moderna USD 610M 584M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03
Xoma USD 94.38M 7.82M 2025-09